- CEO
- Sheng Yong Wu
- Full Time Employees
- 2,115
- Sector
- Distribution services
- Industry
- Medical distributors
- Address
- Shanghai China
- IPO Date
- Sep 25, 2025
- Business
- Shanghai C and D INNOSTIC Medical Technology Group Co., Ltd. is a China-based medical device supply chain solutions provider and distributor specializing in the procurement, distribution, and hospital-integrated logistics management of medical equipment and consumables. Founded in 2010 and headquartered in Shanghai, China, the company operates as a key healthcare supply chain enterprise within the state-owned Xiamen C&D Group ecosystem, serving hospitals, healthcare providers, and regional sub-distributors across China. The company conducts its operations through direct sales, channel distribution, and in-hospital Supply Processing and Distribution (SPD) services. Its product and service portfolio comprises vascular interventional devices, including coronary drug-eluting stents, balloon dilatation catheters, guidewires, neurovascular intervention products, and peripheral vascular consumables; surgical instruments and operating room supplies, including endoscopic staplers, ultrasonic surgical systems, electrosurgical instruments, and wound management materials; in-vitro diagnostic (IVD) systems, encompassing clinical chemistry reagents, immunodiagnostic assays, molecular diagnostic test kits, and laboratory analyzers; medical equipment, comprising ultrasound imaging systems, patient monitoring systems, and endoscopic visualization systems; consumer healthcare and general hospital consumables; and comprehensive healthcare supply chain management services, including smart SPD warehouse design and management, automated dispensing and RFID tracking cabinets, hospital information and ERP systems integration, cold-chain logistics, regulatory compliance, and consignment inventory management, delivered in partnership with global and domestic medical device manufacturers including Medtronic, Boston Scientific, Abbott, Johnson & Johnson, and Mindray. In recent developments, the company completed its initial public offering (IPO) and listed its Class A shares on the ChiNext board of the Shenzhen Stock Exchange in September 2025 under ticker 301584; accelerated the expansion of its SPD smart hospital service contracts across Tier-III Grade-A medical institutions nationwide; adapted its procurement and distribution models to national volume-based procurement (VBP) healthcare reforms; and executed the scheduled market release of approximately 185 million restricted pre-IPO shares alongside ongoing shareholder dividend distributions.